GATC Health Corp. has announced that the new drug candidates discovered by its proprietary artificial intelligence (AI) drug discovery and prediction platform to treat opioid use disorder (OUD) and fentanyl addiction have entered preclinical development.
Recent evidence suggests that spironolactone, a mineralocorticoid receptor antagonist, may modulate alcohol seeking and consumption, for which current therapies are limited.
Epivario Inc. has been awarded a grant of nearly $260,000 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to advance research on its proprietary small-molecule inhibitors designed to reduce alcohol craving responses and help people with alcohol use disorder (AUD) prevent relapse.
A radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI) has shown that intravenous administration of Athersys' MultiStem (invimestrocel) provided benefit in an animal model of acute radiation syndrome (ARS).
RSS
